Literature DB >> 2571403

Double-blind cross-over trial comparing beclomethasone dipropionate and terfenadine in perennial rhinitis.

A C Robinson1, J R Cherry, S Daly.   

Abstract

Eighteen patients with perennial rhinitis were evaluated in this double-blind cross-over trial comparing beclomethasone dipropionate (BDP) aqueous nasal spray with terfenadine tablets. Both treatments were effective in reducing symptom scores but BDP was significantly better than terfenadine in relieving running nose and sneezing (P less than 0.05). BDP also had a greater effect on reducing nasal inflammation than terfenadine. Although the clinicians and patients assessed both therapies to be equi-effective, significantly more patients preferred the BDP treatment (P less than 0.003). Overall, BDP therapy proved more beneficial than terfenadine therapy in this small group of perennial rhinitis sufferers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571403     DOI: 10.1111/j.1365-2222.1989.tb02437.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  5 in total

Review 1.  Intranasal corticosteroids for allergic rhinitis: superior relief?

Authors:  L P Nielsen; N Mygind; R Dahl
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials.

Authors:  J M Weiner; M J Abramson; R M Puy
Journal:  BMJ       Date:  1998-12-12

3.  Treatment of congestion in upper respiratory diseases.

Authors:  Eli O Meltzer; Fernan Caballero; Leonard M Fromer; John H Krouse; Glenis Scadding
Journal:  Int J Gen Med       Date:  2010-04-08

Review 4.  Drug treatment of allergic conjunctivitis. A review of the evidence.

Authors:  G Ciprandi; S Buscaglia; P M Cerqueti; G W Canonica
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

Review 5.  Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy.

Authors:  D McTavish; K L Goa; M Ferrill
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.